SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report: (Date of earliest event reported: August 15, 2008
ETERNAL TECHNOLOGIES GROUP, INC. (Exact name of Registrant as specified in its charter) |
0-27929 (Commission file number) |
Nevada (State or other jurisdiction of incorporation) | 62-1655508 (I.R.S. Employer Identification Number) |
Suite 2007, Golden Central Tower, No. 3037, Jintian Rd., Futian District, Shenzhen, Guangdong, Province, P.R. China |
011-86-22-2721-7020 (Registrant’s telephone number, including area code) |
__________________________________________ (Former name or former address, if changed since last report) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions. (see General Instruction A.2. below).
□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
□ Pre-commencement communications pursuant to Rule 14d-2(b) uner the Exchange Act (17 CFR 240.14d-2(b)).
Item 2.02 Results of Operations and Financial Conditions
Reference is made to the Eternal Technologies Group, Inc. (the “Company”) press release on August15, 2008 attached hereto as Exhibit 99.1 and incorporated by reference herein (including without limiting the information set out in the cautionary statement contained in the press release) relating to the Company’s financial results for the quarter ended June 30, 2008.
Item. 9.01 Financial Statements and Exhibits
(d) Exhibits
Exhibit No. Description
99.1 Press Release issued August 15, 2008
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| ETERNAL TECHNOLOGIES GROUP, INC. | |
| | | |
Date: August 15, 2008 | By: | /s/ Jiansheng Wei | |
| | Jiansheng Wei | |
| | President and Chief Executive Officer | |
| | | |
PRESS RELEASE
Eternal Technologies Group, Inc. (ETLT:OB) today reported earnings for the three months and six months ended June 30, 2008.
For the three months ended June 30, 2008 the company reported revenues of $14,041,480 a 26.7% increase compared to the revenues of $11,084,009 for the corresponding period of prior year. Gross profit for the three months ended June 30, 2008 totalled $4,088,264 an 18.8% increase compared to the $3,440,339 for the prior period. Net income for the three months ended June 30, 2008 totaled $2,613,560 a 36.2% increase or $.05 per share compared to the net income of $1,919,341 or $.04 per share for the corresponding period of the prior year.
For the six months ended June 30, 2008 the company reported revenue of $23,738,014 a 27.7% increase compared to the revenue of $18,588,494 for the six months ended June 30, 2007. Gross profit for the six months June 30, 2007 totalled $6,105,386 an 11.2% increase compared to the gross profit of $5,491,148 for the corresponding period of the prior year. Net income for the six months ended June 30, 2008 totalled $4,608,466 or $.09 per share a 47.1% increase compared to the net income of $3,132,082 or $.07 per share for the six months ended June 30, 2007.
Sales for E-Sea totaled $5,124,005 for the six months ended June 30, 2008 compared with revenue of $3,216,075 an increase of $1,907,930 or 59.3%. E-Sea’s gross margin was $63.5% for the six months ended June 30, 2008.
As of June 30, 2008 the company had cash and cash equivalents of $27,976,450 and working capital of $45,825,953. This compares with cash and cash equivalents of $12,692,479 and working capital of $36,898,802 as of December 31, 2007. In addition to the foregoing, the company also had short-term investments of $14,717,153. As of June 30, 2008 shareholders equity had increased to $83,841,542.
ETERNAL TECHNOLOGIES GROUP, INC. |
CONSOLIDATED CONDENSED BALANCE SHEETS |
June 30, 2008 and December 31, 2007 |
(Amounts in United States Dollars) |
| | | | | | | |
| | | (Unaudited) June 30, | | | (See Note) December 31, | |
| | | 2008 | | | 2007 | |
ASSETS | | | | | | |
Current assets: | | | | | | |
Cash and cash equivalents | | $ | 27,976,450 | | | $ | 12,692,479 | |
Short-term investments | | | 14,717,153 | | | | 13,827,174 | |
Accounts receivable | | | 7,086,207 | | | | 6,274,866 | |
Inventories | | | - | | | | 6,312,236 | |
Prepayments and deposits | | | 14,989 | | | | 14,082 | |
| | | | | | | | | |
Total current assets | | | 49,794,799 | | | | 39,120,837 | |
| | | | | | | | | |
| | | | | | | | |
Property and equipment, net of accumulated depreciation | | | | | | | | |
of $5,033,889 and $4,296,083 at June 30, 2008 and | | | | | | | | |
December 31, 2007, respectively | | | 7,158,822 | | | | 7,161,773 | |
Land use rights, net of accumulated amortization | | | | | | | | |
of $2,324,793 and $2,043,266 at June 30, 2008 and | | | | | | | | |
December 31, 2007, respectively | | | 4,922,217 | | | | 4,765,501 | |
Intangible assets | | | 1,381,734 | | | | 6,571,098 | |
Long term Accounts Receivable | | | | 3,201,490 | | | | - | |
Patent held for lease, net of accumulated amortization | | | | | | | | |
of $302,201 at June 30, 2008 | | | 2,288,095 | | | | - | |
Other Assets | | | 19,063,231 | | | | 17,433,088 | |
| | | | | | | | | |
| Total assets | | $ | 87,810,388 | | | $ | 75,052,297 | |
| | | | | | | | | |
LIABILITIES AND STOCKHOLDERS' EQUITY | | | | | | | | |
Current liabilities: | | | | | | | | |
Notes payable | | $ | 443,366 | | | $ | 443,366 | |
Accounts payable and accrued liabilities | | | 1,378,620 | | | | 1,294,310 | |
Amounts due to related parties | | | 215,672 | | | | 215,295 | |
Income taxes payable | | | 193,992 | | | | 167,764 | |
Deferred Income | | | | 1,699,813 | | | | | |
Derivative financial instrument liability | | | 37,383 | | | | 109,300 | |
| | | | | | | | | |
Total current liabilities | | | 3,968,846 | | | | 2,230,035 | |
| | | | | | | | | |
Stockholders' equity: | | | | | | | | |
Preferred shares - $0.001 par value, 5,000,000 | | | | | | | | |
Authorized, none issued or outstanding | | | - | | | | - | |
Common shares - $0.001 par value; 95,000,000 | | | | | | | | |
Authorized; 55,689,634 shares issued and | | | | | | | | |
Outstanding | | | 55,689 | | | | 52,137 | |
Additional paid - in capital | | | 23,075,753 | | | | 21,303,505 | |
Retained earnings | | | 49,457,232 | | | | 44,848,766 | |
Treasury shares at cost 1,509,703 shares | | | (882,090 | ) | | | (882,090 | ) |
Accumulated other comprehensive income | | | 12,134,958 | | | | 7,499,944 | |
| | | | | | | | | |
Total stockholders' equity | | | 83,841,542 | | | | 72,822,262 | |
| | | | | | | | | |
| Total liabilities and stockholders' equity | | $ | 87,810,388 | | | $ | 75,052,297 | |
| | | | | | | | | |
Note: The balance sheet at December 31, 2007 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by generally accepted accounting principals for complete financial statements. The accompanying notes are an integral part of these unaudited consolidated condensed financial statements |
ETERNAL TECHNOLOGIES GROUP, INC. |
UNAUDITED CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS |
For the Three Months and Six Months ended June 30, 2008 and 2007 |
(Amounts in United States Dollars) |
| | | | | | | | | | | | | | | |
| | | | | Three Months Ended June 30, | | | Six Months Ended June 30, |
| | | | | 2008 | | 2007 | | 2008 | | 2007 |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
Revenue: | $ | | | $ | | | $ | | | $ | |
| Agricultural and genetics sales | | 10,445,408 | | | 9,214,703 | | | 18,160,147 | | | 14,923,370 |
| Medical device sales and services | | 3,301,219 | | | 1,719,093 | | | 5,124,005 | | | 3,216,075 |
| Leasing | | 294,853 | | | 150,213 | | | 453,862 | | | 449,049 |
| | | | | | | | | | | | | | | |
| | Total revenue | | 14,041,480 | | | 11,084,009 | | | 23,738,014 | | | 18,588,494 |
| | | | | | | | | | | | | | | |
Cost of sales and services | | | | | | | | | | | |
| Agricultural and genetics sales | | 8,376,413 | | | 7,002,928 | | | 15,332,910 | | | 12,186,174 |
| Medical device sales and services | | 1,295,390 | | | 501,611 | | | 1,870,931 | | | 1,033,985 |
| Leasing | | 281,413 | | | 139,331 | | | 428,787 | | | 277,187 |
| | | | | | | | | | | | | | | |
| | Total cost of sales and services | | 9,953,216 | | | 7,643,870 | | | 17,632,628 | | | 13,497,346 |
| | | | | | | | | | | | | | | |
Gross profit | | 4,088,264 | | | 3,440,139 | | | 6,105,386 | | | 5,091,148 |
| | | | | | | | | | | | | | | |
Depreciation and amortization expenses | | | | | | | 265,521 | | | 138,458 | | 596,826 275,340 |
| | | | | | | | | | | | | | | |
Selling, general and administrative expenses | | 1,729,081 | | | 1,287,108 | | | 2,508,867 | | | 1,956,574 |
| | | | | | | | | | | | | | | |
Research and development expense | | 286,962 | | | 130,055 | | | 282,780 | | | 129,366 |
| | | | | | | | | | | | | | | |
Income from operations | | 1,806,700 | | | 1,884,518 | | | 2,716,913 | | | 2,729,868 |
| | | | | | | | | | | | | | | |
Other income (expense) | | | | | | | | | | | |
| Interest income | | 60,352 | | | 53,662 | | | 106,341 | | | 103,530 |
| Gain on Sale of Assets | | - | | | - | | | 269,649 | | | (849) |
| Investment Income | | 885,994 | | | 97,541 | | | 1,746,168 | | | 543,338 |
| Change in value of derivative | | | | | | | | | | | |
| | financial instruments | | 15,797 | | | 769 | | | 71,917 | | | (38,111) |
| | | | | | | | | | | | | | | |
| Other income (expense), net | | 962,143 | | | 151,972 | | | 2,194,075 | | | 607,908 |
| | | | | | | | | | | | | | | |
Income before provision for | | | | | | | | | | | |
| income taxes | | 2,768,843 | | | 2,036,490 | | | 4,910,988 | | | 3,337,776 |
| | | | | | | | | | | | | | | |
Provision for income taxes | | 155,283 | | | 117,149 | | | 302,522 | | | 205,694 |
| | | | | | | | | | | | | | | |
Net income | | 2,613,560 | | | 1,919,341 | | | 4,608,466 | | | 3,132,082 |
| | | | | | | | | | | | | | | |
Net income per common share | | | | | | | | | | | |
| Basic and diluted | $ | 0.05 | | $ | 0.04 | | $ | 0.09 | | $ | 0.07 |
| | | | | | | | | | | | | | | |
Weighted average number of | | | | | | | | | | | |
| Common shares outstanding, | | | | | | | | | | | |
| Basic and diluted | | 53,400,825 | | | 47,073,579 | | | 52,765,941 | | | 47,073,579 |
| | | | | | | | | | | | |
The accompanying notes are an integral part of these unaudited consolidated condensed financial statements |
ETERNAL TECHNOLOGIES GROUP, INC. | |
UNAUDITED CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS | |
For the Six Months Ended June 30, 2008 and 2007 | |
(Amounts in United States Dollars) | |
| | | | | | |
| | 2008 | | | 2007 | |
| | | | | | |
Cash flows from operating activities | | | | | | |
Net income | | $ | 4,608,466 | | | $ | 3,132,082 | |
Adjustments to reconcile net income to net cash | | | | | | | | |
Provided by operating activities: | | | | | | | | |
Depreciation and amortization | | | 1,025,614 | | | | 552,527 | |
Gain on sale of assets | | | (269,649 | ) | | | | |
Investment income | | | (1,746,168 | ) | | | | |
Change in value of derivative financial instruments | | | (71,917 | ) | | | (98,693 | ) |
Compensatory stock issuances | | | 710,320 | | | | - | |
Changes in operating assets and liabilities: | | | | | | | | |
Inventories | | | 6,718,520 | | | | 5,430,445 | |
Accounts receivable | | | (184,481 | ) | | | 1,752,930 | |
Short-term investments | | | 494,775 | | | | - | |
Long-term investments | | | 436,567 | | | | - | |
Prepayments and deposits | | | 600,755 | | | | 199,560 | |
Accounts payable and accrued expenses | | | 16,431 | | | | 539,447 | |
| | | | | | | | |
Net cash provided by operating activities | | | 12,339,233 | | | | 11,508,298 | |
| | | | | | | | |
Cash flows from investing activities: | | | | | | | | |
Proceeds from sales of Intangible Assets | | | 1,062,313 | | | | | |
Purchase of fixed assets | | | - | | | | (10,212 | ) |
Purchase of long-term investment | | | - | | | | (4,018,919 | ) |
| | | | | | | | |
Net cash provided by /(used in) investing activities | | | 1,062,313 | | | | (4,029,131 | ) |
| | | | | | | | |
Cash flows from financing activities: | | | | | | | | |
Capital contributed | | | - | | | | 2,304,615 | |
Common Stock Receivable | | | - | | | | 10,176 | |
Proceeds from sales of common stocks | | | 1,065,480 | | | | - | |
| | | | | | | | |
Net cash provided by financing activities | | | 1,065,480 | | | | 2,314,791 | |
| | | | | | | | |
Effect of exchange rate changes on cash | | | 816,945 | | | | 404,974 | |
| | | | | �� | | | |
Net increase (decrease) in cash and cash equivalents | | | 15,283,971 | | | | 10,198,932 | |
| | | | | | | | |
Cash and cash equivalents, beginning of period | | | 12,692,479 | | | | 16,024,123 | |
| | | | | | | | |
Cash and cash equivalents, end of period | | $ | 27,976,450 | | | $ | 26,223,055 | |
Supplemental disclosure of cash flow information: | | | | | | | | |
Interest paid | | $ | - | | | $ | - | |
Income taxes paid | | $ | 159,610 | | | | 205,694 | |
Non-cash investing and financing activities | | | | | | | | |
Receivable from sale of intangible assets | | $ | 3,201,490 | | | $ | - | |
Deferred gain from sale of intangible assets | | $ | 1,099,059 | | | $ | - | |
| | | | | | | | |
The accompanying notes are an integral part of these unaudited consolidated condensed financial statements | |
About Eternal Technologies
Eternal is a major agricultural genetics and biopharmaceutical R&D firm operating in China with the support of the Chinese Government. Eternal's animal breeding division has a strong assets base, cash position and net income .. Eternal has become one of China's leading institutions for biopharmaceutical and biotech research , pure breed cultivation and breed stock production. The Company has secured a key market niche by commercializing gene engineering technologies and providing superior breeding stock, allowing China's citizens the ability to improve their living standards. With the world's largest population, a double-digit national growth rate and entry into the WTO, Eternal Technologies has a playing field set for tremendous opportunity. As a prominent player in the agricultural genetics industry, cash in the bank and an untapped market, Eternal has the potential to become a major player in China's national growth.
For more information please visit website: http://www.eternaltechs.com